Loading stock…

DexCom, Inc. (DXCM) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

DexCom, Inc.

DXCMMarket cap $32BPrice $84.3

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes continuous glucose monitors that let diabetics ditch finger pricks and track blood sugar in real time through a tiny skin sensor. Its devices now sync directly with insulin pumps and Apple Watches, turning diabetes care into a wearable-tech category.

In Bastion Portfolios?

52W Return+27%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+17%9

Revenue Forecast

Rev CAGR (1y)+12%7

Rev CAGR (3y)+11%7

Rev CAGR (5y)+11%8

Earnings Forecast

EPS Growth Y+1+91%10

EPS Growth Y+2+16%8

EPS Growth Y+3+18%8

Quality

Margins

EBIT Margin23%8

Net Income Margin20%8

Free Cash Flow Margin28%9

Debt

Net Debt/EBITDA-0.410

Efficiency

ROE38%10

ROA15%9

Earnings Stability77

GEAR+VERY STRONG85

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)302

P/E Ratio (Forward 3y)232

P/BV12.11

EV Multiples

EV/EBITDA Fwd193

EV/EBIT Fwd253

Yield

Free Cash Flow Yield4.4%6

Dividend Yieldna–

Momentum

Short term

1 month return-0%8

3 month return+14%9

YTD return+27%8

Mid term

Price vs 52wHigh91%8

1 year return+24%8

Long term

3 year return+1%3

5 year return-36%2

Risk Shield

Price Risk

Beta1.13

Volatility40%4

Free Cash Flow

Free Cash Flow Margin28%9

Free Cash Flow Yield4.4%6

Quality

ROCE28%10

Earnings Stability77

Net Debt/EBITDA-0.410

02Growth

Is it actually growing, and how fast?

DXCMDexCom

Revenue FY25$4.0B

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+11%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+91%10

EPS growth, FY27E+16%8

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 11%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 18%/yr vs revenue 11%/yr), so margins should widen.

WATCH

Revenue grew 17%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+14%9

YTD return+27%8

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+24%8

3-year return+1%3

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 24% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+14%) and so far this year (+27%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+1.3% over three years and -36% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on DexCom. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DXCMDexCom

Revenue FY25$4.0B

GROWTH RATING↗

STRONG76 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+17%9

Revenue, next 1Y+12%7

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+11%8

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+91%10

EPS growth, FY27E+16%8

EPS growth, FY28E+18%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 76% of companies worldwide.

Revenue grew 17%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.7/10

The runway holds up: revenue is set to grow 11%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 18%/yr vs revenue 11%/yr), so margins should widen.

WATCH

Revenue grew 17%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

STRONG67 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-0%8

3-month return+14%9

YTD return+27%8

MID & LONG-TERM▾SCORE

% of 52-week high91%8

1-year return+24%8

3-year return+1%3

5-year return-36%2

MOMENTUM ASSESSMENT

STRENGTHS

It's up 24% over the past year, but 9% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+0%), over three months (+14%) and so far this year (+27%).

WATCH

None flagged.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+1.3% over three years and -36% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on DexCom. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community